- 作者：Mika A. Sovak ; Martee L. Hensley ; Jakob Dupont ; Nicole Ishill ; Kaled M. Alektiar ; Nadeem Abu-Rustum ; Richard Barakat ; Dennis S. Chi ; Paul Sabbatini ; David R. Spriggs and Carol Aghajanian
- 刊名：Gynecologic Oncology
- 出版年：2006
- 期刊代码：295_00908258
- 类别：med
- 出版时间：November 2006
- 卷：103
- 期：2
- 页码：451-457
- 文件大小：181 K
Purpose.To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection.Patients and methods.
Patients with stage III/IV endometrial cancer with less than 2 cm of disease after surgical resection who received TC in the adjuvant setting were retrospectively identified and are the subject of this analysis. Data were extracted from electronic medical records. Disease recurrence was documented by radiologic progression or pathologic tissue review. We obtained Institutional Review Board approval before initiating this study.
Results.
Forty-eight patients were eligible for analysis—24 (50%) with stage IV disease, 29 (60%) with serous or clear cell tumor histology and 43 (90%) with FIGO grade 3 tumors. All patients underwent surgical resection; 10 (21%) of the 48 patients received adjuvant radiation therapy in addition to chemotherapy. Forty-three patients (90%) received 6 cycles of paclitaxel (175 mg/m2) and carboplatin (area under the curve of 5–6) every 3 or 4 weeks, and 44 (92%) completed all planned cycles of treatment. With a median follow-up of 20 months (range, 6–92), 29 patients (60%) recurred, with a 3-year overall survival rate of 56%. The median time to progression for all patients was 13 months (95%CI 10, 18) with a median OS of 47 months (95%CI, 30—upper limit not achieved).
Conclusion.
TC is a well tolerated, active regimen in the treatment of resected, high-risk stage III and IV endometrial cancer that warrants further investigation.